US Pharma’s China Question: Risk, Resilience, and Engagement

Global pharmaceutical supply chains are more integrated than ever. With its cost advantages and comprehensive industrial ecosystem, China has become a critical source of pharmaceutical inputs that underpin the US healthcare system and business operations in the life sciences sector. Although this interdependence is well recognized, managing it requires greater coordination among policymakers, regulators, and industry stakeholders.